Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Donanemab (LY3002813) in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Donanemab

First Posted Date: 2022-09-09

Last Posted Date: 2024-10-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT05533411

Locations: 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳
Peking University First Hospital, Beijing, Beijing, China

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Phase 2

Active, not recruiting

Conditions: Rheumatoid Arthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

Interventions: Drug: Peresolimab
Drug: Placebo

First Posted Date: 2022-08-26

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 491

Registration Number: NCT05516758

Locations: 🇺🇸
St Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸
Arizona Arthritis & Rheumatology Research, PLLC, Mesa, Arizona, United States
🇺🇸
Wolverine Clinical Trials, Tustin, California, United States

and more 124 locations

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Mirikizumab

First Posted Date: 2022-08-25

Last Posted Date: 2024-07-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 396

Registration Number: NCT05515601

Locations: 🇺🇸
Labcorp Clinical Research LP, Dallas, Texas, United States
🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸
QPS, Springfield, Missouri, United States

and more 2 locations

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Phase 3

Recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Imlunestrant
Drug: Tamoxifen
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane

First Posted Date: 2022-08-24

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 6000

Registration Number: NCT05514054

Locations: 🇺🇸
Summit Cancer Care, PC, Savannah, Georgia, United States
🇺🇸
Saint Alphonsus Regional Medical Center, Boise, Idaho, United States
🇺🇸
Staten Island University Hospital, Staten Island, New York, United States

and more 684 locations

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Drug: LY3484356

First Posted Date: 2022-08-22

Last Posted Date: 2024-08-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 17

Registration Number: NCT05509790

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Wannan Medical College Yijishan Hospital, Wuhu Shi, Anhui, China
🇨🇳
The Third Hospital of Nanchang, Nanchang, Jiangxi, China

and more 1 locations

A Study of Imlunestrant (LY3484356) in Healthy Women

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam
Drug: Imlunestrant

First Posted Date: 2022-08-22

Last Posted Date: 2023-01-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT05509816

Locations: 🇺🇸
LabCorp CRU, Inc., Dallas, Texas, United States

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Phase 3

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: Mirikizumab

First Posted Date: 2022-08-22

Last Posted Date: 2024-12-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 90

Registration Number: NCT05509777

Locations: 🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States
🇮🇱
Hadassah University Hospital, Ein Kerem,, Jerusalem, Israel
🇯🇵
National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan

and more 83 locations

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Phase 3

Recruiting

Conditions: Alzheimer Disease
Dementia
Neurocognitive Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Mental Disorders
Neurodegenerative Diseases

Interventions: Drug: Donanemab
Drug: Placebo

First Posted Date: 2022-08-19

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1500

Registration Number: NCT05508789

Locations: 🇪🇸
Fundació ACE, Barcelona, Barcelona [Barcelona], Spain
🇫🇷
Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau, Tours, Centre, France
🇵🇱
Centrum Badan Klinicznych PI-House sp. z o.o., Gdansk, Pomorskie, Poland

and more 194 locations

A Study of LY3873862 in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: LY3873862
Drug: Placebo

First Posted Date: 2022-08-08

Last Posted Date: 2024-08-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 84

Registration Number: NCT05492201

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

Phase 1

Terminated

Conditions: Healthy
Dermatitis, Atopic

Interventions: Drug: Placebo
Drug: LY3844583

First Posted Date: 2022-08-03

Last Posted Date: 2024-05-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 102

Registration Number: NCT05486208

Locations: 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
🇯🇵
P-one clinic, Hachioji, Tokyo, Japan
🇺🇸
Parexel Early Phase Unit at Glendale, Glendale, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy